Health

Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.

Lilly Asia Ventures has returned to reinvest in the renal disease therapy developer through a series B-plus round totalling $54.5m.

Samsung-backed automation software developer Rezilion secured $30m while IGC Hospitality took part in restaurant management technology provider MarginEdge's $18m series B round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Bristol Myers Squibb helped the cell encapsulation technology developer raise cash that will help fund its international growth.

The stem cell therapy developer, exploiting research from Digital Photonics and Nanoscience Laboratory, has set up a US subsidiary.

The B cell therapy developer has publicly launched with $50m in series A financing from investors including Illumina Ventures.

Yatsen has participated in a series A-plus round for the diversified drug developer, six months after its closed a $60m series A.

UPS is buying delivery service Roadie having helped it raise $62m while heart disease treatment developer Nectero Medical secured $19.5m in a Boston Scientific-led round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.